The neuromelanin of human substantia nigra: physiological and pathogenic aspects. 2004

Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
Institute of Biomedical Technologies-CNR 20090 Segrate (Milano), Italy.

Neuromelanin (NM) accumulates as a function of age in normal human substantia nigra (SN) but is relatively depleted in the SN of patients with Parkinson disease (PD). Several studies have been performed to further our understanding of the role of NM in neuronal aging and neurodegenerative mechanisms of PD. To this purpose, NM from human SN was isolated and its structure and molecular interactions were investigated. Cysteinyl-dopamine was shown to be one precursor of NM synthesis. A striking affinity of NM for specific metals, lipids, drugs and pesticides was found in vitro, and in animal and human brain postmortem studies. Because of these affinities, NM seems to play a protective role in the human brain by blocking toxic molecules. On the other hand, experiments in cell culture indicate that NM can activate microglia, eliciting the release of cytotoxic factors that can induce neurodegeneration.

UI MeSH Term Description Entries
D008543 Melanins Insoluble polymers of TYROSINE derivatives found in and causing darkness in skin (SKIN PIGMENTATION), hair, and feathers providing protection against SUNBURN induced by SUNLIGHT. CAROTENES contribute yellow and red coloration. Allomelanins,Melanin,Phaeomelanins
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras

Related Publications

Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
September 1991, Biochimica et biophysica acta,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
January 2014, Neurotoxicity research,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
January 1990, Journal of neural transmission. Parkinson's disease and dementia section,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
August 2003, Biochemical pharmacology,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
May 1994, Journal of neurochemistry,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
April 2000, Journal of neurochemistry,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
January 2003, Journal of neural transmission. Supplementum,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
May 2002, Journal of neural transmission (Vienna, Austria : 1996),
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
February 2005, Journal of neurochemistry,
Fabio A Zucca, and Giuseppe Giaveri, and Mario Gallorini, and Alberto Albertini, and Marco Toscani, and Gianni Pezzoli, and Ralph Lucius, and Henrik Wilms, and David Sulzer, and Shosuke Ito, and Kazumasa Wakamatsu, and Luigi Zecca
January 2002, Neurotoxicology and teratology,
Copied contents to your clipboard!